FDA grants orphan designation to antifungal drug candidate CD101 IV

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.

May 16, 2025

Vol.51 No.19

By Katie Goldberg

Capitol Hill

Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges

In back-to-back congressional hearings earlier this week, HHS Secretary Robert F. Kennedy Jr. said that the massive staff and budget cuts over which he has presided during his nearly four months on the job as well as even bigger cuts still looming on the horizon are a part of a single plan.

May 16, 2025

Vol.51 No.19

By Jacquelyn Cobb and Claire Marie Porter

Clinical

Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

Natalie Phelps, a 43-year-old mother of two, has stage 4 colorectal cancer. She has become a central figure in the controversy over the dysfunction the Trump administration’s RIFs and budget cuts have brought to NIH.

An opportunity for Trump: Position U.S. cancer science to lead the world

Last November, the American public voted on America First causes, which include the greatest scientific discovery and achievement enterprise in the world: The National Institutes of Health. NIH has made America first in biomedical science for the past century.

First exhibit at Museum of Medicine and Biomedical Discovery to focus on the history of cancer research
From despair to discovery to triumph

For those who have spent their entire careers in oncology, cancer is our world. We see it as something to be studied, understood, controlled, cured, or prevented.

May 16, 2025

Vol.51 No.19

By Mace L. Rothenberg

City of Hope research showcases innovation at 2025 AACR annual meeting

City of Hope researchers at AACR.City of Hope presented more than 74 sessions at this year’s American Association for Cancer Research Annual Meeting in Chicago, highlighting breakthroughs in diagnostics, treatment options and AI-powered precision medicine.

May 16, 2025

Vol.51 No.19

By City of Hope

FDA grants orphan designation to antifungal drug candidate CD101 IV

YOU MAY BE INTERESTED IN

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges

Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

An opportunity for Trump: Position U.S. cancer science to lead the world

First exhibit at Museum of Medicine and Biomedical Discovery to focus on the history of cancer research
From despair to discovery to triumph

City of Hope research showcases innovation at 2025 AACR annual meeting

Renew today!

Subscriber content

Never miss an issue!

Login

FDA grants orphan designation to antifungal drug candidate CD101 IV

YOU MAY BE INTERESTED IN

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient livesIn a time of uncertainty, “react to the knowns, not the fear”

Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFsTo avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges

Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reducedNCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

An opportunity for Trump: Position U.S. cancer science to lead the world

First exhibit at Museum of Medicine and Biomedical Discovery to focus on the history of cancer researchFrom despair to discovery to triumph

City of Hope research showcases innovation at 2025 AACR annual meeting

Never miss an issue!

Login

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges

Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

First exhibit at Museum of Medicine and Biomedical Discovery to focus on the history of cancer research
From despair to discovery to triumph